Pharmaceutical major Lupin has informed that it has settled the litigation relating to the launch of generic version of Effexor XR capsule, which is patented by Wyeth, in the US.

Under the terms of settlement with Wyeth, Lupin would be now free to commercially launch the generic version of Effexor XR after June 2011.

It should be noted that Lupin had earlier filed an application with the US Food and Drug Administration for launching the drug patented by Wyeth in the US market.

While, on the other hand Wyeth has filed litigation against the Indian drug major in the US alleging infringement of its patent for the drug.

Effexor XR (venlafaxine hydrochloride) extended-release capsules are indicated for the treatment of major depressive disorder. The drug had reported annual sales worth $3.01 billion in US.